About OnyvaxSciencePress ReleasesClinical TrialsCareersContact
Onyvax - oncology vaccines 

Cancer Vaccines

Onyvax' s Approach

S.A.B.



Investors
Science image

Products in Development

Onyvax's products are being developed for the treatment of prostate cancer, one of the most common cancers today. Onyvax believes its therapies will be able to prolong life for cancer patients while helping to maintain a high quality of life.

Onyvax-P is a Cell Vaccine being developed for prostate cancer treatment. The current study follows the successful completion of a Phase IIa trial in which almost half of the patients showed significant decreases in their PSA velocity. In addition, the time to disease progression was lengthened relative to that normally expected in a population at this stage of the disease (Clinical Cancer Res (2005) 11:4469-4478).

Onyvax-P consists of a combination of inactivated cell lines that are representative of different stages of the disease.

 



© 1998-2009 Onyvax Ltd. All Rights Reserved